血液生物学标记物与急性缺血性卒中患者的神经功能转归被引量：2

Blood biological markers and neurological outcome in patients with acute ischerrdc stroke

导出

摘要急性缺血性卒中具有高发病率、高致死率和高致残率等特点，严重影响着中老年人群的健康，寻找影响急性缺血性卒中患者神经功能转归的相关因素，并对其干预是该领域的研究热点之一。近年来的研究显示，基质金属蛋白酶-9、神经元特异性烯醇化酶、S-100B蛋白、脑利钠肽、和肽素、血脂、血糖等血液学指标均可能与急性缺血性卒中患者的神经功能转归有关。 Acute ischemic stroke is characterized by high morbidity, high mortality and high disability. It seriously affects the health of middle-aged and elderly persons. Searching for the relevant factors that influence the neurological outcome in patients with acute ischemic stroke and interfering with them are one of the research hotspots in this field. Studies in recent years have shown that matrix metalloproteinase-9, neuron- specific enolase, S-100B protein, brain natriuretic peptide, copeptin, blood lipids, blood glucose and other hematological parameters may be associated with the neurological outcome in patients with acute ischemic stroke.

作者杨梨李长清

机构地区重庆医科大学附属第二医院神经内科

出处《国际脑血管病杂志》北大核心 2012年第3期227-231,共5页 International Journal of Cerebrovascular Diseases

关键词卒中脑缺血生物学标记治疗结果 Stroke Brain Ischemia Biological Markers Treatment Outcome

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献39

1Lloyd-Jones D, Adarm R, Carnethon M, et al; American Heart Association Statistics Corrttee and Stroke Statistics Subcorrttee. Heart disease and stroke statistics--2009 update: a report from the An-can Heart Association Statistics Cotrttee and Stroke Statistics Subconttee. Circulation, 2009, 119: 480-486.
2Brouns R, Wauters A, De Sureloose D, et al. Biochemical markers for blood-brain bri dysfunction in acute ischemic stroke correlate with evolution d outcome. Eur Neurol, 2011, 65: 23-31.
3Rarrtys-Femmdez M, Bellolio MF, Stead LG. Matrix rretalloproteinase-9 as a marker for acute ischenc stroke: a systematic review. J Stroke Covasc Dis, 2011, 20: 47-54.
4Lucivero V, Prontera M, Mezzapesa DM, et al. Different roles of matrix metaUoproteinases-2 and -9 after human ischaernic stroke. Nettrol Sci, 2007, 28: 165-170.
5Vukasovic I, Tesija-Kttna A, Topic E, et al. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med, 2006, 44: 428-434.
6Rodriguez-Y6fiez M, Castellanos M, Blanco M, et al. New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. Neurology, 2006, 67: 1973-1978,.
7Ning M, Furie KL, Koroshetz WJ, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology, 2006, 66: 1550-1555.
8Jauch F, Lindsell C, Broderick J, et al; NINDS rt-PA Stroke Study Group. Associmion of serial biochm'ical markers with acute ischemic stroke: the National Institute of NeuroloNcal Disorders and Stroke recombinant tissue plasn-mon activator Stroke Study. Stroke, 2606, 37: 2508-2513.
9Wunderlich MT, Lins H, Skalej M, et al. Neuron-specific enolase and tau protein as neurobiochemicnA markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006, 108: 558-563.
10Worthrrmnn H, Tryc AB, Goldbecker A, et al. The temporal profile of infianmmtory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis, 2010, 30: 85-92.